Blood, 132(Suppl.1). AMER SOC HEMATOLOGY d'Amore, F, Leppa, S, da Silva, M G, Relander, T, Lauritzsen, G F, Brown, P D N, Pezzutto, A, Doorduijn, J K, Weidmann, E, van Gelder, M, Van Hoof, A, Christiansen, I, Fagerli, U M, Hagberg, H, Lugtenburg, P J, Walewski, J, Wu, K L, Demuynck, H M, Fijnheer, R, Christensen, J H, Jankovska, M, Josefsson, P L, Kluin-Nelemans, H, Mariz, J M, Merup, M A, Noesslinger, T, Van den Neste, E, Zijlstra, J M, Hopfinger, G, Prochazka, V I T, Jantunen, E, Boudova, L, Cabecadas, J, Chott, A, Delabie, J M A, de Leval, L, Diepstra, A, Karjalainen-Lindsberg, M-L, Noergaard, P, Rosenwald, A, Rymkiewicz, G, Sundström, C, Truemper, L, Wulf, G, Chong, L, Bouska, A, Smith, L, Gisselbrecht, C, Ziepert, M, Loeffler, M, Liestol, K, Steidl, C, Gascoyne, R D, Scott, D W, Altmann, B, Iqbal, J, Chan, W C & Toldbod, H 2018, ' Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant ', Blood, vol. 132, no. Suppl. 1, pp. 998 . https://doi.org/10.1182/blood-2018-99-110429 d'Amore, F, Leppa, S, da Silva, M G, Relander, T, Lauritzsen, G F, Brown, P D N, Pezzutto, A, Doorduijn, J K, Weidmann, E, van Gelder, M, Van Hoof, A, Christiansen, I, Fagerli, U M, Hagberg, H, Lugtenburg, P J, Walewski, J, Wu, K L, Demuynck, H M, Fijnheer, R, Christensen, J H, Jankovska, M, Josefsson, P L, Kluin-Nelemans, H, Mariz, J M, Merup, M A, Noesslinger, T, Van den Neste, E, Zijlstra, J M, Hopfinger, G, Prochazka, V I T, Jantunen, E, Boudova, L, Cabecadas, J, Chott, A, Delabie, J M A, de Leval, L, Diepstra, A, Karjalainen-Lindsberg, M-L, Noergaard, P, Rosenwald, A, Rymkiewicz, G, Sundstrom, C, Truemper, L, Wulf, G, Chong, L, Bouska, A, Smith, L, Gisselbrecht, C, Ziepert, M, Loeffler, M, Liestol, K, Steidl, C, Gascoyne, R D, Scott, D W, Altmann, B, Iqbal, J, Chan, W C & Toldbod, H 2018, ' Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant ', Blood, bind 132, nr. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-110429